High-cost patients diagnosed with opioid abuse have higher rates of chronic comorbidities and mental health conditions compared with lower-cost patients, which highlights the need to consider the complete medical and psychosocial patient history, according to a new study published in the Journal of Managed Care & Specialty Pharmacy.
High-cost patients diagnosed with opioid abuse have higher rates of chronic comorbidities and mental health conditions compared with lower-cost patients, which highlights the need to consider the complete medical and psychosocial patient history, according to a new study published in the Journal of Managed Care & Specialty Pharmacy.
The researchers used retrospective claims data to describe the characteristics of patients diagnosed with opioid abuse who also have disproportionately high healthcare costs for the purpose of assisting providers in targeting interventions at these costly patients. The study period included a 12-month observation period centered on the date of first opioid abuse diagnosis.
“An improved understanding of these costly patients is relevant for physicians, managed care organizations, and other stakeholders who have an interest in addressing opioid abuse and reducing the associated health care costs,” the authors wrote.
The patients in the top 20% of total healthcare costs among patients diagnosed with opioid abuse were considered “high-cost patients”—they accounted for two-thirds of costs—while the remaining 80% of patients were considered “lower-cost patients.”
High-cost patients were older, more likely to be female, and had a higher comorbidity burden as well as higher rates of conditions such as chronic pulmonary disease and mild or moderate diabetes. They also had higher rates of psychotic disorders.
During the observation period, the mean cost for high-cost patients was $89,177 compared with $11,653 for lower-cost patients. High-cost patients not only were more likely to use medical resources, but they did so with greater intensity. So not only were they more likely to have at least 1 inpatient visit, but they had longer inpatient stays.
The authors recommended that future research examine high-cost patients with opioid abuse in Medicaid, Medicare, and the uninsured population.
“In addition to targeting the subset of patients that accounts for a disproportionate share of the economic burden of opioid abuse, other multifaceted efforts, such as provider education, coordinated programs that address medical and social needs, prescription drug monitoring programs, and new drug formulations intended to deter opioid abuse, may be necessary to address prescription opioid abuse at the societal level,” the researchers concluded.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
2 Commerce Drive
Cranbury, NJ 08512